



Abbott Diagnostics



FutureFit Solutions™

During the past 50 years,
Abbott Diagnostics has created
more than 600 products
to meet the changing needs
of clinical laboratories around the world.
We continue our commitment to innovation
with new products to help you
meet the challenges of today . . .
and the days ahead.



The future is not a gift — it is an achievement.

Harry Lander

A Tradition of Innovation

Introducing ARCHITECT™ . . . a family of instruments designed with your future in mind. ARCHITECT is a breakthrough approach that will transform the laboratory into a unified testing environment. With the ARCHITECT family, you will be able to combine multiple instruments and technologies into a single consolidated workstation . . . Integrate different technologies to lab automation configurations and existing lab information systems . . . Customize instrument solutions to meet your menu and throughput needs . . . And share reagents, disposables, components, and software across a family of instruments.



Intelligent Integration begins with **i2000™**, the first instrument in the ARCHITECT family. The **i2000** is a high-volume immunoassay analyzer that uses Abbott's new CHEMIFLEX™ technology to provide up to 200 tests per hour, with 25 reagents on board. Multiple instruments can be combined for throughput of up to 800 tests per hour — with up to 100 reagent positions.



The future is purchased by the present.

Samuel Johnson

A U n i f i e d F u t u r e

A Bright Outlook

Abbott Diagnostics again leads the way in hematology systems with **CELL-DYN® 3200**, the newest CELL-DYN five-part differential hematology analyzer. With patented M.A.P.S.S.™ technology, the system provides a dual white count, optical platelets, and a Resistant RBC Mode in a highly reliable, compact instrument.



Another first from CELL-DYN — **CELL-DYN SMS™**, the first automated slide preparation system. The SMS will smear, label, and stain up to 120 slides per hour — and gives you consistent blood films with minimal operator involvement. The SMS can operate as a stand-alone unit or in conjunction with CELL-DYN counters.




CELL-DYN innovations continue with **CELL-DYN Workcell™**, the world's first second-generation hematology workstation automation system. The unit is designed to automate all processes that impact hematology testing decisions — prior to, and including, the reporting of results.




My interest is in the future because I am going to spend the rest of my life there.

Charles E. Kettering




Introducing **Alcyon™**, Abbott's new benchtop chemistry system. With an extensive menu, walkaway capability, and throughput of up to 300 tests per hour, Alcyon is what you've been looking for in a benchtop chemistry analyzer.



Abbott continues its leadership in infectious disease testing with the **LCx®** analyzer. Through amplification of target DNA, LCx provides highly accurate results — with assays for chlamydia and gonorrhea. Coming soon: the LCx MTB® assay for tuberculosis. Products under development include tests for HIV and hepatitis.

With the acquisition of **MediSense®**, Abbott has entered the critical area of blood glucose testing. The **MediSense Precision-G™** blood glucose testing system is designed for hospital bedside use — providing instant results via a built-in printer. Advanced biosensor



technology ensures accurate results, and the instrument's **MICROFLO™** test strip minimizes dependence on sample volume.

E x p e c t t h e B e s t



All things must change to something new.

H. W. Longfellow

F o r e s i g h t

The **AxSYM**[®] System has revolutionized immunoassay testing by combining random, continuous, and immediate access capabilities with a broad menu of over 50 assays. With up to 120 tests per hour, AxSYM gives you the high throughput you need in a demanding testing environment. In 1998, **AxSYM 2**^{***} will offer further enhancements in data and sample management, continuing the AxSYM Highly Recommended[™] tradition.



Abbott continues its diagnostic innovations with an expanding menu of AxSYM assays, including: **AxSYM CA 15-3**^{*} for the quantitative measurement of CA 15-3 assay values in human serum or plasma . . .

AxSYM CA 125^{*} for the quantitative measurement of OC 125 reactive determinants in human serum . . . **AxSYM B12** for the quantitative measurement of vitamin B12 in human serum or plasma . . . **AxSYM Folate**^{*} for the quantitative measurement of folate in human serum, plasma, or red blood cells . . .

And **AxSYM Troponin I**^{***} for the quantitative measurement of troponin-I in human serum or plasma.



^{*}Pending FDA clearance
^{**}Available outside the U.S.
^{***}In development



Light tomorrow with today.

Elizabeth Barrett Browning



To learn more about FutureFit Solutions™,
visit Abbott Diagnostics at the
1997 AACC Meeting.

Booth 1031

July 20-24, 1997

Atlanta, GA



ABBOTT DIAGNOSTICS
A DIVISION OF ABBOTT LABORATORIES

©1997 Abbott Laboratories AP1033/R1-25-June 1997 Printed in USA